Ovarian Epithelial Tumor

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
FDA (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
EMA (1) FDA (2)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (1)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
FDA (1)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
EMA (1) FDA (1)	FOLR1 positive	Ovarian Epithelial Tumor	Mirvetuximab soravtansine